Market Definition
Non-Small Cell Lung Cancer (NSCLC) is the most common & epithelial type of lung cancer that occurs in different forms, viz., Squamous Cell Carcinoma (SCC), Large Cell Carcinoma (LCC), & Adenocarcinoma. Smoking is mainly responsible for NSCLC since smokers are more likely to develop NSCLC. However, it is observed that adenocarcinoma has also occurred in patients with no smoking history.
Further, as the prevalence of lung cancers is rising worldwide, the demand for their diagnosis & treatments is also surging rapidly, which, in turn, is compelling governments & leading biopharma companies to boost drug developments & distributions in order to cater to the unmet patient needs for efficient & safe NSCLC treatments.
Market Insights
The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide.
Observing the growing influx of NSCLC patients globally, governments of different countries are investing massively in the healthcare sector to strengthen the oncology department, including the NSCLC, and encourage the leading biopharmaceutical companies to discover novel therapeutics with enhanced efficacy & safety. As a result, the expansion of various players and the emergence of local companies are seen extensively worldwide.
| Report Coverage | Details |
|---|---|
| Study Period | Historical Data: 2017-20 |
| Base Year: 2021 | |
| Forecast Period: 2022-27 | |
| CAGR (2022-2027) | 11.2% |
| Regions Covered | North America: The US, Canada, Mexico |
| South America: Brazil, Rest of South America | |
| Europe: Germany, The UK, France, Spain, Italy, Rest of Europe | |
| Asia-Pacific: China, Japan, India, South Korea, Rest of Asia Pacific | |
| Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa | |
| Key Companies Profiled | Allergan (AbbVie), AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb, Eisai Co., Ltd, Eli Lilly and Company, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Other |
| Unit Denominations | USD Million/Billion |
Additionally, growing awareness among people about the availability of diagnosis & various treatments for NSCLC through government engagement in campaigns, advertisements, etc., i.e., portraying a rising patient pool across different countries, is further augmenting the overall market growth.
The leading biotechnology & pharmaceutical companies like Pfizer Inc. are developing & introducing sophisticated targeted therapies like Vizimpra & Lorbrena for NSCLC patients, i.e., another crucial aspect projecting remunerative prospects for the Global Non-Small Cell Lung Cancer (NSCLC) Market through 2027.
